TABLE 1

Biodistribution of 111In-NLS-7G3 and 111In-NLS-BM4 mAbs or F(ab′)2 Fragments in NOD/SCID Mice Implanted Subcutaneously with CD123-Transfected Raji or Nontransfected Raji Tumor Xenografts

Without IgG2a preadministration111In-NLS-7G3 with IgG2a preadministrationF(ab′)2 fragments
Organ111In-NLS-7G3111In-NLS-BM4BM4 excess7G3 excess111In-NLS-7G3111In-NLS-BM4
Blood0.2 ± 0.10.2 ± 0.14.0 ± 1.0*7.6 ± 1.7*1.4 ± 0.80.6 ± 0.1
Liver4.0 ± 2.32.0 ± 0.17.3 ± 1.08.0 ± 0.53.5 ± 1.91.3 ± 0.4
Spleen35.4 ± 13.931.6 ± 2.427.0 ± 4.136.1 ± 3.95.0 ± 4.611.0 ± 0.2
Kidneys6.2 ± 1.74.9 ± 0.59.4 ± 1.012.0 ± 0.69.6 ± 2.413.7 ± 4.4
Muscle1.0 ± 0.91.0 ± 0.20.9 ± 0.31.0 ± 0.21.0 ± 0.40.6 ± 0.1
Raji-CD1231.4 ± 0.50.7 ± 0.414.7 ± 2.8*,‡5.5 ± 3.1*7.2 ± 3.80.3 ± 0.1
RajiNDND2.1 ± 0.6NDNDND
  • * Significantly different (P < 0.05), compared with 111In-NLS-7G3 or 111In-NLS-BM4 without preadministration of excess IgG2a.

  • Significantly different (P < 0.05), compared with 111In-NLS-7G3 and 111In-NLS-BM4 F(ab′)2.

  • Significantly different (P < 0.05), compared with nontransfected Raji tumors.

  • Data are %ID/g (mean ± SD).

  • ND = Not determined.

  • Results were obtained at 72 h after injection for intact IgG2a and at 48 h after injection for F(ab′)2 fragments.